Analytical Data
-
基因名
CD27/TNFRSF7
-
简介
CD27/TNFRSF7 Protein lacks conserved residue(s) crucial for feature annotation propagation, suggesting a unique structural characteristic. This peculiarity may influence CD27's functional properties within the TNFR superfamily, emphasizing the need for further investigation to understand its specific roles and regulatory mechanisms in cellular processes. CD27/TNFRSF7 Protein, Cynomolgus (HEK293, mFc) is the recombinant cynomolgus-derived CD27/TNFRSF7 protein, expressed by HEK293 , with C-mFc labeled tag. The total length of CD27/TNFRSF7 Protein, Cynomolgus (HEK293, mFc) is 172 a.a., with molecular weight of 50-66 kDa.
- Application
-
别名
CD27; TNFRSF7; S152; T14; Tp55
-
种属
Cynomolgus
-
表达系统
HEK293
-
标签
C-mFc
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
XP_005569963
-
表达区间
A20-R191
-
分子量
50-66 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CD27, also known as TNFRSF7, is a type I transmembrane protein that belongs to the tumor necrosis factor receptor (TNFR) superfamily. It plays a crucial role in regulating immune responses, particularly in T and B lymphocytes, by promoting cell proliferation, survival, and differentiation upon binding its ligand, CD70. The interaction between CD27 and CD70 is vital for effective immune system activation and has implications in various diseases, including autoimmune disorders and cancer. Research on recombinant CD27/TNFRSF7 proteins has gained traction due to their potential therapeutic applications, including immune checkpoint modulation and enhancing anti-tumor immunity. Recombinant forms of CD27 can be utilized in both basic research and clinical settings to explore their function in immune signaling pathways and to develop novel immunotherapies. Understanding the structural and functional properties of CD27, including its signaling mechanisms and ligand interactions, is essential in harnessing its potential for therapeutic purposes. With advancements in recombinant DNA technology, the production of CD27/TNFRSF7 as a therapeutic protein offers promise for improving immune responses in cancer patients and those with immune deficiencies. This research not only aims to elucidate the biology of CD27 but also to leverage its properties for the development of innovative immune-related therapies.
